Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. Its lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; and in Phase III clinical trials for recurrent platinum-resistant ovarian cancer, as well as for Phase II clinical trials for iodine-resistant differentiated thyroid cancer. The company is also developing VB-111, which is in Phase I clinical trials for the treatment of patients with various types of advanced metastatic cancer types, including thyroid cancer, neuroendocrine cancer, renal cell carcinoma, and lung cancer. In addition, it is developing VB-511, an anti-angiogenic candidate for oncology; VB-211 and VB-411, which are pro-angiogenic candidates for the treatment of peripheral vascular diseases; VB-201, a Lecinoxoid-based compound for the control of chronic inflammatory disorders; and VB-600 that is in pre-clinical stage for targeting of MOSPD2 for immuno-oncology and anti-inflammatory applications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was founded in 2000 and is headquartered in Modi'in, Israel.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VBLT
CUSIPN/A
Phone972-8993-5000
Debt
Debt-to-Equity RatioN/A
Current Ratio6.59
Quick Ratio6.59
Price-To-Earnings
Trailing P/E Ratio-6.85
Forward P/E Ratio-3.15
P/E GrowthN/A
Sales & Book Value
Annual Sales$13.86 million
Price / Sales5.50
Cash FlowN/A
Price / CashN/A
Book Value$1.88 per share
Price / Book1.36
Profitability
EPS (Most Recent Fiscal Year)($0.37)
Net Income$-10,130,000.00
Net MarginsN/A
Return on Equity-28.67%
Return on Assets-24.29%
Miscellaneous
Employees37
Outstanding Shares29,900,000
Vascular Biogenics (NASDAQ:VBLT) Frequently Asked Questions
What is Vascular Biogenics' stock symbol?
Vascular Biogenics trades on the NASDAQ under the ticker symbol "VBLT."
How were Vascular Biogenics' earnings last quarter?
Vascular Biogenics Ltd (NASDAQ:VBLT) announced its earnings results on Thursday, May, 17th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.21) by $0.03. The biopharmaceutical company earned $0.16 million during the quarter. View Vascular Biogenics' Earnings History.
When is Vascular Biogenics' next earnings date?
What price target have analysts set for VBLT?
4 brokers have issued 1-year target prices for Vascular Biogenics' stock. Their forecasts range from $3.00 to $4.00. On average, they anticipate Vascular Biogenics' share price to reach $3.3333 in the next twelve months. View Analyst Ratings for Vascular Biogenics.
Who are some of Vascular Biogenics' key competitors?
Some companies that are related to Vascular Biogenics include Ra Pharmaceuticals (RARX), BioSpecifics Technologies (BSTC), Strongbridge Biopharma (SBBP), resTORbio (TORC), Axovant Sciences (AXON), Galectin Therapeutics Inc. Common Stock (GALT), Kadmon (KDMN), Kindred Biosciences (KIN), Ocular Therapeutix (OCUL), Biofrontera (BFRA), CTI BioPharma (CTIC), Selecta Biosciences (SELB), ASLAN PHARMACEUTICALS ADR REP 5 (ASLN), AVEO Pharmaceuticals (AVEO) and Athersys (ATHX).
Who are Vascular Biogenics' key executives?
Vascular Biogenics' management team includes the folowing people:
- Prof. Dror Harats, CEO & Director (Age 61)
- Mr. Amos Ron, CFO, Principal Accounting Officer & Company Sec. (Age 63)
- Dr. Erez Feige Ph.D., M.B.A., VP of Bus. Operations (Age 44)
- Dr. Eyal Breitbart Ph.D., VP of Research & Operations (Age 51)
- Dr. Naamit Sher Ph.D., VP of Drug Devel. & Regulatory (Age 64)
Has Vascular Biogenics been receiving favorable news coverage?
Press coverage about VBLT stock has trended somewhat positive this week, Accern Sentiment Analysis reports. Accern scores the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Vascular Biogenics earned a news sentiment score of 0.17 on Accern's scale. They also gave news coverage about the biopharmaceutical company an impact score of 45.71 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.
How do I buy shares of Vascular Biogenics?
Shares of VBLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Vascular Biogenics' stock price today?
One share of VBLT stock can currently be purchased for approximately $2.55.
How big of a company is Vascular Biogenics?
Vascular Biogenics has a market capitalization of $82.22 million and generates $13.86 million in revenue each year. The biopharmaceutical company earns $-10,130,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. Vascular Biogenics employs 37 workers across the globe.
How can I contact Vascular Biogenics?
Vascular Biogenics' mailing address is 8 HaSatat St, Modi'in L3, 7178106. The biopharmaceutical company can be reached via phone at 972-8993-5000 or via email at [email protected]
MarketBeat Community Rating for Vascular Biogenics (VBLT)
MarketBeat's community ratings are surveys of what our community members think about Vascular Biogenics and other stocks. Vote "Outperform" if you believe VBLT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VBLT will underperform the S&P 500 over the long term. You may vote once every thirty days.
